NASDAQ: PMN - ProMIS Neurosciences, Inc.

Rentabilité sur six mois: -45.78%
Rendement en dividendes: 0.00%
Secteur: Healthcare

Calendrier des promotions ProMIS Neurosciences, Inc.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise ProMIS Neurosciences, Inc.

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils.

plus de détails
The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

IPO date 2007-07-17
ISIN CA74346M4065
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.promisneurosciences.com
Цена ао 1.94
Changement de prix par jour: -3.23% (0.93)
Changement de prix par semaine: -2.17% (0.92)
Changement de prix par mois: -4.26% (0.94)
Changement de prix sur 3 mois: -29.69% (1.28)
Changement de prix sur six mois: -45.78% (1.66)
Changement de prix par an: -21.74% (1.15)
Evolution du prix sur 3 ans: +800% (0.1)
Evolution du prix sur 5 ans: +542.86% (0.14)
Evolution des prix sur 10 ans: 0% (0.9)
Evolution des prix depuis le début de l'année: -2.17% (0.92)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 0 0
P/BV 2.24 7
P/E 0 0
EV/EBITDA 0.2826 10
Total: 4.63

Efficacité

Nom Signification Grade
ROA, % -73.22 0
ROE, % -265.68 0
Total: 0

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Devoir

Nom Signification Grade
Debt/EBITDA 0 10
Total: 9.6

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % 0 0
Rentabilité Ebitda, % 212.45 10
Rentabilité EPS, % 8.71 2
Total: 6.4
Plus de détails

Établissements Volume Partager, %
Sphera Funds Management Ltd. 1834042 9.67
Ally Bridge Group (NY) LLC 1066674 5.63
Affinity Asset Advisors, LLC 265958 1.4
Northeast Financial Consultants Inc 100000 0.53
IEQ CAPITAL, LLC 30799 0.16
Fiduciary Trust Company (MA) 20008 0.11
Kingsview Wealth Management, LLC 11100 0.06
Claret Asset Management Corp 10830 0.06
UBS Group AG 5926 0.03
Bank of America Corporation 1666 0.01



Superviseur Titre d'emploi Paiement Année de naissance
Dr. Neil R. Cashman M.D. Co-Founder, Co-Chairman of Scientific Advisory Board, Chief Scientific Officer & Director 333.8k 1952 (73 année)
Mr. Gavin T. Malenfant Chief Operating Officer 413.49k 1964 (61 année)
Mr. Daniel E. Geffken M.B.A. Chief Financial Officer 89.99k 1957 (68 années)
Dr. Johanne Kaplan Ph.D. Chief Development Officer 263.07k 1960 (65 années)
Dr. Ernest D. Bush Ph.D. Head of Pharmacology/Toxicology & Senior Consultant N/A
Dr. David Wishart Ph.D. Chief Physics Officer N/A
Mr. Dennis Chen Ph.D. Head of Manufacturing & Senior Consultant N/A
Dr. Larry Douglas Altstiel M.D., Ph.D. Chief Medical Officer N/A 1950 (75 années)
Mr. Neil K. Warma M.B.A. President, Interim CEO & Director 40k 1963 (62 année)
Mr. Eugene W. Williams Co-Founder & Chairman 1959 (66 années)

Adresse: Canada, Toronto. ON MS E, 1920 Yonge Street - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://www.promisneurosciences.com